{"filing":{"accession_number":"0001753926-26-001190","cik":"0001266806","ticker":"VANI","company_name":"Vivani Medical, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"vani-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001190/vani-20260715.htm"},"events":[{"id":18308,"run_id":16456,"accession_number":"0001753926-26-001190","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The disclosure reports a presentation at the Emerging Growth Conference with an update that the Company's first dosing of SLIM-1 is expected in August 2026. This is a material operational milestone for a clinical-stage biotech company — the timing of first-in-human dosing is a key development event that would affect investor assessment of the company's progress. While not fitting a specific named category, this is clearly an operational/strategic disclosure about a clinical development milestone.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17076,"accession_number":"0001753926-26-001190","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure reports a presentation at the Emerging Growth Conference with an update that the Company's first dosing of SLIM-1 is expected in August 2026. This is a material operational milestone for a clinical-stage biotech company — the timing of first-in-human dosing is a key development event that would affect investor assessment of the company's progress. While not fitting a specific named category, this is clearly an operational/strategic disclosure about a clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:31:49.272005+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17076,"accession_number":"0001753926-26-001190","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure reports a presentation at the Emerging Growth Conference with an update that the Company's first dosing of SLIM-1 is expected in August 2026. This is a material operational milestone for a clinical-stage biotech company — the timing of first-in-human dosing is a key development event that would affect investor assessment of the company's progress. While not fitting a specific named category, this is clearly an operational/strategic disclosure about a clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:31:49.272005+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-16"}]}